Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001737287-20-000021
Filing Date
2020-04-23
Accepted
2020-04-23 16:34:54
Documents
6
Period of Report
2019-12-31
Effectiveness Date
2020-04-23

Document Format Files

Seq Description Document Type Size
1 DEF 14A allo-20200423xdef14axproxy.htm DEF 14A 879360
2 ceocomp4620201.jpg GRAPHIC 28387
3 drafproxyimage11.jpg GRAPHIC 19512
4 drafproxyimage12.jpg GRAPHIC 19512
5 neo2019compmix4620201.jpg GRAPHIC 33650
6 qualificationstable_4820201.jpg GRAPHIC 56289
  Complete submission text file 0001737287-20-000021.txt   1097740
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38693 | Film No.: 20811461
SIC: 2836 Biological Products, (No Diagnostic Substances)